Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500625PMID: 29999685
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 850649-61-5
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of alogliptin during breastfeeding. An alternate drug may be preferred, especially while nursing a newborn or preterm infant. Monitoring of the breastfed infant's blood glucose is advisable during maternal therapy with alogliptin.[1]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Berlin CM, Briggs GG. Drugs and chemicals in human milk. Semin Fetal Neonatal Med. 2005;10:149–59. [PubMed: 15701580]
Substance Identification
Substance Name
Alogliptin
CAS Registry Number
850649-61-5
Drug Class
Breast Feeding
Lactation
Hypoglycemic Agents
Incretins
Dipeptidyl-Peptidase IV Inhibitors
DPP-4 Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.